Ideal for processing capacities of 1 to 125L in process development and small-scale production! Supplied with SUS316L hardware.
The "Centramate Tangential Flow System for Laboratory Use" is suitable for processing capacities ranging from 1 to 125 liters in process development and small-scale production. Membrane cassette removal is easy without disassembling the system piping. By simply adding membrane cassettes [each cassette has a filtration area of 0.1 m²], the filtration area can be easily expanded to 0.5 m². Additionally, due to the same flow path length, linear scale-up to larger process systems is possible. There is a documented case of desalting antisense oligonucleotides obtained from solid-phase synthesis using the Centramate 1K membrane for nucleic acid synthesis applications. 【Features】 - Easily expand the filtration area to 0.5 m² by simply adding membrane cassettes - Linear scale-up to larger process systems is possible - Easy removal of membrane cassettes - Provided with SUS316L hardware - Various membranes are available for a wide range of applications Boos, J.A. et al., Nucleic Acids Research. 41 e145 (2013)
Inquire About This Product
basic information
【Specifications (Partial)】 ■Dimensions: 13.2 cm × 22.6 cm × 16.7 cm ■Minimum effective filtration area (per cassette): 0.1 m² ■Maximum effective filtration area (for 5 cassettes): 0.5 m² ■Standard residual liquid volume (per cassette): 20 mL or less ■Recommended operating pressure: 30 kPa to 520 kPa *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Applications】 ■ Processing at lab scale and pilot scale ■ Concentration of biomolecules ■ Recovery and purification of biomolecules ■ Diafiltration and desalting ■ Fractionation of mixed molecular solutions *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
